Heimdall Power raises $25 Million USD Series B to Accelerate Power Grid Optimization Globally
16.7.2024 13:00:00 CEST | Business Wire | Press Release
Heimdall Power, the global leader in power grid optimization, today announced a $25 million USD capital raise in a Series B financing. The round was co-led by the international energy company Orlen, Nordic cleantech fund NRP Zero, and the Steinsvik Family Office. Existing shareholders, including Investinor, Eviny, Hafslund, Lyse, and Sarsia Seed, participated in the round with a combined $8.5 million USD.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716656922/en/
New and existing investors united in Heimdall Power’s Oslo HQ to celebrate the successful funding round. Photo: Jola McDonald
Founded in 2016, Heimdall Power delivers software and sensors for the monitoring of overhead power lines. The technology enables electric utilities to increase transmission capacity in their high-voltage power grids by 40% on average, while simultaneously improving the safety and efficiency of their operations. Heimdall Power’s solutions allow utilities to optimize existing power grid assets, reducing or delaying the need for expensive infrastructure upgrades, while making utilities better prepared to meet the growing electricity demand fueled by the ongoing energy transition.
The sphere-shaped sensor-units, called Neurons by Heimdall Power, gather live data that allows the company’s advanced software to assess the actual transmission line capacity in real-time. This way, utilities can harness the increased capacity made available by Dynamic Line Ratings (DLR), moving on from the traditional static or seasonal line ratings that limit grid operators from utilizing power grids in a dynamic fashion.
The Neuron’s unique design and remarkable ability to squeeze more capacity out of the existing infrastructure has earned it recognition as a “Magic Ball” by top global media outlets like the Wall Street Journal, Forbes, and Yahoo. The sensor units can be installed in a matter of seconds on live power lines through a patented autonomous drone system, providing unrivaled scalability and efficiency while ensuring safety of workers. By combining them with their digital sibling, the AI-powered Virtual Neuron, Heimdall Power is the first to offer precise monitoring of overhead lines at system-wide scale.
“We have reached many key milestones in Heimdall Power during the past year, but this is the biggest yet and the timing is perfect. The U.S. government recently announced a goal to upgrade 100,000 miles of transmission lines in the next few years, and powered by this Series B round, we’ll do our fair share to fulfill that vision,” said Jørgen Festervoll, CEO of Heimdall Power. “This funding gives us fuel to grow internationally, as we continue to build our organization with the best people and industry experts in the world. It will also allow us to make further investments in our tech-development, taking scalability to the next level as we strengthen our position as the clear world-leader within Grid-Enhancing Technologies,” Festervoll concluded.
Heimdall Power is trusted by more than 40 utilities in 17 countries across Europe, Asia, and the U.S. The company recently caught the attention of the U.S. government after launching the largest grid optimization project in the United States with Minnesota’s Great River Energy, and was subsequently invited to the White House in Washington D.C. for a summit on Grid Modernization.
“Heimdall Power has built itself a unique position as an enabler for the ongoing energy transition with, fast-increasing electricity demand and queues of renewables waiting to get connected. As the owner of one of Poland’s four utilities, we have observed the growing challenges power grids around the world are facing” said Marek Garniewski, President of the Management Board at Orlen VC. “The ability of Heimdall’s solutions to increase grid capacity by 40% is not just impressive, it's transformative. Combined with the increasingly strong governmental interest and new mandates coming out of the U.S. and Europe we are happy to be part of this investment opportunity, supporting Heimdall Power in their ongoing international growth journey.”
Sharing in the excitement about the company’s future, Patrick Sandahl, Investment Director at Investinor, added: "As both an investor and board member, I've witnessed Heimdall Power's remarkable journey firsthand. Their technology has already started to reshape the entire energy sector. This funding round is a testament to the team's vision and execution, cementing Heimdall Power’s pivotal role in modernizing power grids globally."
About Heimdall Power
Heimdall Power is a technology company that specializes in power grid optimization, making the world's grids smarter, more capable and more sustainable. Heimdall Power’s technology is trusted by over 40 utilities in 17 countries, across Europe, Asia and in the United States, where it has successfully increased power grid capacity for companies like Swissgrid, Austrian Power Grid, TenneT and Great River Energy by as much as 40% on average. The company designs and develops smart software solutions and industrial devices in support of its mission to enable a swift, secure and affordable energy transition around the world. Heimdall Power was founded in 2016 with European headquarters in Oslo, Norway and US headquarters located in Charlotte, North Carolina.
About ORLEN Group
The ORLEN Group is an integrated multi-utility energy company listed in the prestigious global Fortune Global 500. It was the first company in the region to declare achieving total emission neutrality in 2050. Thanks to the recent acquisitions and mergers, it became one of the 150 largest companies in the world. The company operates on 10 home markets: Poland, Czech Republic, Germany, Lithuania, Slovakia, Hungary, Austria, Canada, Norway and Pakistan.By the end of this decade, ORLEN will invest over PLN 320 billion to implement strategic projects, of which approximately 40% will be allocated to green investments, including wind energy at sea and on land, photovoltaics, biogas and biomethane, biofuels, electromobility, green hydrogen and synthetic fuels.
About NRP Zero
NRP Zero is an Oslo-based industrial cleantech fund manager investing in late-stage venture companies accelerating the energy transition and optimizing resource efficiency with a positive impact beyond the Nordics. Through active engagement with companies’ management teams and stakeholders, we seek to amplify long-term returns while delivering positive and sustainable environmental outcomes. The investment team comprises of five professionals with longstanding experience in active ownership at the cross-section of industry, energy and finance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716656922/en/
Contacts
Peter Gørbitz | Head of Marketing & Communications
+47 905 12 662 | peter@heimdallpower.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom